Halo Therapeutics
Halo Therapeutics is dedicated to leveraging leading-edge technologies to create highly targeted small molecule treatments, focusing on diseases with significant unmet medical needs. Their approach involves structure-based drug design, structural biology, computational chemistry, and molecular sciences to develop innovative therapies, including antivirals and obesity treatments. The company emphasizes patient-centric solutions and collaborates with industry and academic partners to advance their pipeline of novel therapeutics.
Industries
Nr. of Employees
small (1-50)
Halo Therapeutics
Ty Merlin Caerphilly Business Park, Van Road, Caerphilly, Wales, CF83 3GS
Products
Pan-coronavirus antiviral small molecule (preclinical candidate)
A small-molecule antiviral designed to bind a conserved fatty-acid binding pocket in coronavirus spike proteins, discovered and validated using structural, computational, biophysical and biochemical methods; intended for prophylactic or at-home therapeutic use.
Oral small-molecule maintenance therapy for obesity (preclinical program)
Development program for an oral small-molecule appetite suppressant aimed at long-term weight maintenance by modulating gut–brain signalling pathways (e.g., FFAR1/GPR40).
Pan-coronavirus antiviral small molecule (preclinical candidate)
A small-molecule antiviral designed to bind a conserved fatty-acid binding pocket in coronavirus spike proteins, discovered and validated using structural, computational, biophysical and biochemical methods; intended for prophylactic or at-home therapeutic use.
Oral small-molecule maintenance therapy for obesity (preclinical program)
Development program for an oral small-molecule appetite suppressant aimed at long-term weight maintenance by modulating gut–brain signalling pathways (e.g., FFAR1/GPR40).
Services
Academic and industry collaborations, licensing and partnering to co-develop lead molecules and expand biological insights.
Engagement with institutional and private investors and support for investment or licensing discussions.
Academic and industry collaborations, licensing and partnering to co-develop lead molecules and expand biological insights.
Engagement with institutional and private investors and support for investment or licensing discussions.
Expertise Areas
- Structure-based drug discovery
- Structural biology
- Computational chemistry and physics-based modelling
- Small-molecule medicinal chemistry
Key Technologies
- Cryo-electron microscopy (cryo-EM)
- X-ray crystallography
- Computational chemistry
- Structure-based drug design
News & Updates
Halo Therapeutics received the prestigious Golden Ticket Award from Novo Nordisk in 2025, recognizing their innovative research and development efforts.
Celebrating the achievements of Halo's CTO, Professor Christiane Schaffitzel, on International Women in Science Day.
Research links the COVID pandemic to an increase in diabetes among children and teenagers.
Structural biology research using cryo-electron microscopy uncovers how fatty acids activate FFAR1, a potential target for metabolic diseases.
Review of Halo's novel synthetic agonists for GPR40/FFAR1, highlighting their unique chemistry.
The founders of Halo Therapeutics published a review in Science and an article in Forbes, highlighting their scientific achievements.
Halo Therapeutics received the prestigious Golden Ticket Award from Novo Nordisk in 2025, recognizing their innovative research and development efforts.
Celebrating the achievements of Halo's CTO, Professor Christiane Schaffitzel, on International Women in Science Day.
Research links the COVID pandemic to an increase in diabetes among children and teenagers.
Structural biology research using cryo-electron microscopy uncovers how fatty acids activate FFAR1, a potential target for metabolic diseases.
Review of Halo's novel synthetic agonists for GPR40/FFAR1, highlighting their unique chemistry.
The founders of Halo Therapeutics published a review in Science and an article in Forbes, highlighting their scientific achievements.